Methods of use of antimicrobial compounds against pathogenic mycoplasma bacteria

Abstract

This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, including Mycoplasma bacteria, such as Mycoplasma pneumoniae.

1 . (Canceled)  
     
     
         2 . (Canceled)  
     
     
         3 . A method of treating or preventing a bacterial infection by pathogenic  Mycoplasma  bacteria comprising the step of administering an antibacterially effective amount of a composition comprising a gemifloxacin compound, or an antibacterially effective derivative thereof, to a mammal suspected of having or being at risk of having an infection with pathogenic  Mycoplasma  bacteria.  
     
     
         4 - 7 . (Canceled)  
     
     
         8 . The method of  claim 3  wherein said mammal is a human.  
     
     
         9 - 11 . (Canceled)  
     
     
         12 . The method of  claim 3  wherein said pathogenic  Mycoplasma  bacteria is a member of the genus  Mycoplasma.    
     
     
         13 . The method of  claim 12  wherein said bacteria is selected from the group consisting of  Mycoplasma hominis  and  Mycoplasma fermentans.    
     
     
         14 . The method of  claim 12  wherein said bacteria is selected from the group consisting of  Mycoplasma pneumoniae, Mycoplasma genitalium , and  Mycoplasma penetrans.    
     
     
         15 . The method of  claim 3  wherein said bacteria is a member of the genus  Ureaplasma.    
     
     
         16 . The method of  claim 15  wherein said bacteria is  Ureaplasma urealyticum.    
     
     
         17 . The method according to  claim 3  wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.  
     
     
         18 . The method according to  claim 17  wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.  
     
     
         19 . The method according to  claim 18  wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.  
     
     
         20 . The method according to  claim 12  wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.  
     
     
         21 . The method according to  claim 20  wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.  
     
     
         22 . The method according to  claim 21  wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.  
     
     
         23 . The method according to  claim 13  wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.  
     
     
         24 . The method according to  claim 23  wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.  
     
     
         25 . The method according to  claim 24  wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.  
     
     
         26 . The method according to  claim 14  wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.  
     
     
         27 . The method according to  claim 26  wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.  
     
     
         28 . The method according to  claim 27  wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.  
     
     
         29 . The method according to  claim 15  wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.  
     
     
         30 . The method according to  claim 29  wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.  
     
     
         31 . The method according to  claim 30  wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.  
     
     
         32 . The method according to  claim 16  wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.  
     
     
         33 . The method according to  claim 32  wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.  
     
     
         34 . The method according to  claim 33  wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.